Please login to the form below

Not currently logged in

Nycomed strengthen CEE presence

Swiss company buys 20 branded generics from sanofi-aventis and Zentiva

Nycomed has agreed to buy 20 branded generic products from sanofi-aventis and Zentiva in an attempt to strengthen its market position in Central and Eastern Europe, in particular in the Czech Republic and Slovakia.

Under the terms of the deal, Nycomed will acquire a portfolio of branded generic drugs in the Czech Republic, Slovakia, Romania, Hungary, Estonia and Bulgaria, with an annual turnover of around €17m. In addition, Nycomed will also assume future production.

As part of the deal, Nycomed has purchased Zentiva's well-established hypnotic hypnogen (zolipidem) in the Czech Republic, Slovak Republic and Estonia.

Most of the purchased products are in the Czech Republic and include a strong franchise of beta-blockers (Vasocardin, Betaxa and Tenoloc), which will bolster the company's cardiovascular business around Ebrantil. Other brands include Trental, Flavobion and Ercefuryl.

"These brands will complement our local portfolios very well," said Frank Rotmann, area manager Central and Eastern Europe, Nycomed.

The purchase will be completed as an asset transfer transaction – no further financial details of the deal were available. The European Commission and the Czech Antimonopoly Office have approved the deal, which is expected to close in September 2009. 

3rd August 2009


Featured jobs

Subscribe to our email news alerts


Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...